Abstract
Olsalazine sodium (5,5'-azodisalicylic acid (OLZ] was given to eight healthy volunteers as a 10 mg i.v. bolus dose and as a 1 g oral dose with and without food. To five fasting participants single oral doses of 2 g and 4 g were given. Blood and urine were collected during three weeks after each dose and were assayed for OLZ, a conjugate identified as a sulphate of OLZ (OLZs), 5-aminosalicylic acid (5-ASA), and N-acetyl-5-aminosalicylic acid (ac-5-ASA). The study showed that: 1. OLZ had a very short elimination half-life, mean 56 min. 2. OLZ was absorbed from the intestinal tract to a very small extent, as seen from the low systemic availability and low urinary excretion, 2.3% and 0.31% respectively, for a 1 g dose taken fasting. 3. OLZ was present in the serum partly as a conjugate, which was identified as an O-sulphate. Following the i.v. dose the serum half-life of the O-sulphate was estimated to be 7 days. 4. Food intake did not influence the systemic availability of OLZ and ac-5-ASA. 5. There was no dose-dependent increase of OLZ absorption with single doses up to 2 g, but a 4-g dose showed a more than two-fold increase in the individual peak serum concentration and in the systemic availability of OLZ. However, there was no significant increase in the mean residence time (MRT) for OLZ or in the serum concentration of either 5-ASA or ac-5-ASA at a dose of 4 g.
MeSH Terms
Administration, Oral
Adult
Aminosalicylic Acids/administration & dosage,pharmacokinetics,urine
Aspirin/blood,urine
Chromatography, High Pressure Liquid
Food
Humans
Injections, Intravenous
Male
Spectrometry, Fluorescence
Spectrophotometry, Ultraviolet
Chemicals
Aminosalicylic Acids
Aspirin
olsalazine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ryde E M
Department of Human Pharmacology, Pharmacia AB, Uppsala, Sweden.
Ahnfelt N O
References (20)
20 references, click to expand
-
Transit of pharmaceutical dosage forms through the small intestine.
Gut. 1986 Aug;27(8):886-92
PMID: 3732895
-
Kinetics of 5-aminosalicylic acid after jejunal instillation in man.
Br J Clin Pharmacol. 1983 Dec;16(6):738-40
PMID: 6661362
-
Nephrotoxic lesions from 5-aminosalicylic Acid.
Br Med J. 1972 Jan 15;1(5793):152-4
PMID: 20791817
-
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.
Lancet. 1981 Aug 8;2(8241):270-1
PMID: 6114321
-
A new method for the determination of the binding capacity of testosterone-estradiol-binding-globulin in human plasma.
J Steroid Biochem. 1973 Sep;4(5):537-50
PMID: 4782683
-
The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.
Scand J Gastroenterol. 1980;15(6):715-9
PMID: 7010522
-
Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
Gut. 1987 Feb;28(2):196-200
PMID: 3557190
-
Biliary excretion of olsalazine sodium in humans.
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):17-24
PMID: 3609069
-
Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
Gut. 1980 Jul;21(7):632-5
PMID: 6107263
-
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
Gut. 1982 Dec;23(12):1081-7
PMID: 7173720
-
5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
Gastroenterology. 1982 Nov;83(5):1062-70
PMID: 7117789
-
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
Gastroenterology. 1984 Jun;86(6):1496-500
PMID: 6143704
-
Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.
J Pharm Sci. 1979 Oct;68(10):1323-5
PMID: 41931
-
Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.
Gastroenterology. 1986 Apr;90(4):1024-30
PMID: 2868964
-
An experiment to determine the active therapeutic moiety of sulphasalazine.
Lancet. 1977 Oct 29;2(8044):892-5
PMID: 72239
-
Rate limiting steps in metabolite kinetics: formation of 5-acetylaminosalicylate after administration of 5-aminosalicylate.
J Pharm Pharmacol. 1982 Aug;34(8):536-8
PMID: 6126573
-
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).
Gut. 1973 Dec;14(12):923-6
PMID: 4150435
-
Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
Gastroenterology. 1985 Mar;88(3):717-22
PMID: 2857146
-
Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.
Eur J Clin Pharmacol. 1992;43(2):189-92
PMID: 1425876
-
Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.
Scand J Gastroenterol. 1983 Jan;18(1):107-11
PMID: 6675167